| Antigen: |
BCR-ABL |
| Relevance: |
The BCR gene is involved
in the 9:22 translocation that generates the Philadelphia
chromosome both in chronic myeloid leukemia (CML) and
in a proportion of cases of acute lymphocytic leukemia
(ALL). A 5' bcr sequence becomes fused to an abl sequence
(including tyrosine kinase domain sequences) from chromosome
9 and results in the production of a chimaeric BCR-ABL
protein with enhanced kinase activity. These antibodies
may be useful for studies of the oncogene and have potential
diagnostic and prognostic applications. |
| Clone: |
7c6 |
| Subclass: |
IgG2a |
| Applications: |
Western blot, Immunoprecipitation, Immunofluorescence |
| Immunogen: |
Bcr686 thyroglobulin cojugate (Sequence: SSINEEITPRRQS) |
| Reactivity: |
Human |
| Species raised in: |
Mouse: Balb/c |
| Fusion partner: |
P3x63 Ag8 |
| Recommended growth conditions: |
DMEM + 5% FCS |
| References: |
Dhut S et al. 1988. Oncogene
3:561-566 
Walker LC et al. 1987. Nature 329:851-853 |
| Notes: |
- |
For further information about antibodies from CRT or to discuss sales or licensing options, please contact us at reagents@cancertechnology.com
Please note that CRT supplies to distributors only. However, we are happy to direct researchers to the appropriate commercial party to obtain antibodies within our portfolio. Click here to view disclaimer information. |
